Why This Matters

Roche is a direct competitive threat because it has a Phase II program in Obesity · GLP-1 Receptor Agonist (Berobenatide) and could narrow Pfizer's development lead — particularly against Berobenatide.

Competitive Assessment

Threat type

direct competitor

Development stage

Phase II

Stage gap

Stage comparison unavailable — competitor development phase not fully evidenced.

Market share risk

Moderate share risk if competitor advances before the signal sponsor establishes label leadership.

Strategic Action

Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.

Overlap Analysis

Source Analysis

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintide’s efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity A Phase II multi-arm trial evaluating e

Source: Roche

Related Signal

Pfizer's Berobenatide Shows Promising Phase 2b Results for Monthly Dosing in Obesity Management

Competitor Position